Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers

Shanghai HEP Pharmaceutical Co., Ltd.35 enrolled

Overview

To evaluate the safety and tolerability of Hepalatide(L47) and characterize the clinical pharmacokinetics in healthy volunteers.

This is a randomized, double-blinded, dose escalating, phase Ib trial, which will be conducted in No. 302 Hospital of China. There are three cohorts at dose of 4.2mg, 6.3mg and 8.4mg. All healthy volunteers will be randomized into Hepalatide or placebo group at 4:1 rate, all healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be observed for 3 days.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Hepatitis B， Chronic

Interventions

HepalatideDRUG

There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.

PlaceboDRUG

There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Ages between 18 and 45 years * BMI Index between 19 and 25 (BMI=weight/height2) * Normal previous history and physical exam * No drug and alcohol abuse * No illness in 4 weeks and no drug therapy in 2 weeks * No blood donation or subject not sampled in 3 months * Consistent and correct use of recommended methods of birth control for men and women * Good compliance with study protocol * Understand and agree to sign a consent form Exclusion Criteria: * Infection with HAV, HBV, HCV, HEV, HIV, EBV or CMV * Abnormal and clinical significance test of physical examination, vital signs, blood routines, urine routines, liver and kidney functions, coagulation indicator, electrolyte, glucose, blood lipid, thyroid functions, chest X-Ray, ECG, B ultrasound of gallbladder, spleen and kidney, AFP ,and CEA * Positive for anti-Pre-S1 antibody * Women being pregnant or nursing, or with abnormal sex hormones, B ultrasound of ovaries/uterus proliferative diseases or breast mass * Unable to quit smoking in trial * Subject with little chance of enrollment (i.e. the weak) * Subject not suitable to join the trial under other circumstances judged by investigator.

Locations (1)

302 Military Hospital

Beijing, China

Outcomes

Primary Outcomes

Healthy participants with treatment-related adverse events as assessed by "guiding principle of grading standards for the adverse reactions in clinical trials of vaccine for prevention" or CTCAE v4.0

Time frame: 6 months

Secondary Outcomes

Maximum Plasma Concentration (Cmax)

Time frame: 6 months

Area under the plasma concentration versus time curve (AUC)

Time frame: 6 months

half-time

Time frame: 6 months

apparent volume of distribution

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.